stockrowAbbVie Inc.
ABBV Healthcare Drug Manufacturers General
AbbVie Inc.’s revenue for fiscal 2025 (year ended December 2025) was $61.2 billion, up 8.57% from fiscal 2024.
- Revenue
- +10.3%
- EPS
- +2,270.0%
- Free cash flow
- +9.97%
- Total debt
- +17.7%
Quarter to September 2026, against a year earlier
Follow ABBV
Alert me
AbbVie Inc. (ABBV) Revenue growth
AbbVie Inc.'s revenue growth over the twelve months to 30 September 2026 was 10.7%, up 2.1 percentage points from fiscal 2025 (8.57%). Over the past ten years it has ranged from −6.44% (fiscal 2023) to 37.7% (fiscal 2020); the current reading is higher than 45% of that period. That is above the Drug Manufacturers General industry median of 6.72% and above the Healthcare sector median of 7.80%.
Revenue growth, annual
Embed this chart
Annual newest first
| Period | Revenue growth | Change (points) |
|---|---|---|
| FY2025 | 8.57% | 4.86 |
| FY2024 | 3.71% | 10.15 |
| FY2023 | −6.44% | (9.74) |
| FY2022 | 3.30% | (19.39) |
| FY2021 | 22.7% | (15.00) |
| FY2020 | 37.7% | 36.12 |
| FY2019 | 1.57% | (14.51) |
| FY2018 | 16.1% | 6.02 |
| FY2017 | 10.1% | (2.10) |
| FY2016 | 12.2% | (2.36) |
Quarterly newest first
| Period | Revenue growth | Change (points) |
|---|---|---|
| Sep 2026 | 10.3% | 0.16 |
| Jun 2026 | 10.2% | (2.27) |
| Mar 2026 | 12.4% | 2.39 |
| Dec 2025 | 10.0% | 0.94 |
| 43 more quarters | Free account |
Against its own ten years
Revenue growth against peers
| Company | Revenue growth |
|---|---|
| LLY Eli Lilly and Company compare | 45.5% |
| ABBV AbbVie Inc. | 10.7% |
| AMGN Amgen Inc. compare | 8.15% |
| JNJ Johnson & Johnson compare | 7.80% |
| AZN AstraZeneca PLC compare | 7.32% |
| GILD Gilead Sciences, Inc. compare | 6.54% |
| MRK Merck & Co., Inc. compare | 4.89% |
| NVS Novartis AG compare | 1.76% |
| PFE Pfizer Inc. compare | 1.34% |
| Drug Manufacturers General industry median | 6.72% |
| Healthcare sector median | 7.80% |
| Market median | 7.58% |
What Revenue growth is
Revenue Growth shows how fast a company’s sales are rising or falling compared with the same period a year earlier.
(Revenue − Revenue a year earlier) ÷ |Revenue a year earlier|
More on ABBV
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement